Anti-Human CD279 Recombinant Antibody(Camrelizumab)
-
产品编号
YR1436
-
别名
科研级 Camrelizumab ( 坎利珠单抗 ), Anti-CD279 Recombinant Antibody, Research Grade Camrelizumab
-
规格
- 1mg
- 5mg
Alias | 科研级 Camrelizumab ( 坎利珠单抗 ), Anti-CD279 Recombinant Antibody, Research Grade Camrelizumab |
Catalog Number | YR1436 |
Molecular Name | Camrelizumab |
Size | 1mg, 5mg |
Clonity | Monoclonal |
Purity | >95% as determined by SDS-PAGE |
Concentration | 1mg/ml |
Antibody Isotype | IgG4 Kappa |
Formulation | PBS, pH7.5 |
Background | Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitionitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials. |
CAS Number | 1798286-48-2 |
Application | ELISA, IHC, IF, IP, FCM, Block |
Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Remarks | This product is for research use only. |
Shipping Condition | Shipped on ice packs. |
Target | CD279[Homo sapiens] |